SLC6A5 and neuropathic pain: Right now clinical trials for the GlyT2 inhibitor VVZ‐149 (Figure 1; 6) from Vivozone, which additionally acts as antagonist at the 5‐HT2A and P2X3 receptors, for the treatment of postoperative pain are in progress.[13, 14, 15, 16] Furthermore, most recent research aims at the development of lipid‐based GlyT2 inhibitors like N‐arachidonylglycine (NAGly; Figure 1; 4) or N‐oleoylglycine (NOGly; Figure 1; 5),[1, 17, 18, 19, 20, 21] which show positive effects in neuropathic pain models but fewer side effects.